1Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011,183 : 788-824. 被引量：1
2Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK[J]. Thorax,2011,66:462- 467. 被引量：1
6Cortijo J, Cerda-Nico|as M, Serrano A, et al. Attenuation by o- ral N- acetylcysteine of bleomycin - induced lung injury in rats [J]. Eur Respi r J,2001,17 (6) : 1228-1235. 被引量：1
7Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med,2005,353:2229-2242. 被引量：1
8Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo con- trolled trial[J]. Am J Respir Crit Care Med, 2008,178:948-955. 被引量：1
9Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo- controlled trial of pirfenidone in patients with idiopathic pul- monary fibrosis [J].Am J Respir Crit Care Med,2005,171:1040- 1047. 被引量：1
10Bouros D. Pirfenidone for idiopathic pulmonary fibrosis[J].Lancet, 2011,377 : 1727-1729. 被引量：1
8Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative [J]. Cancer Res, 1996, 56(1): 100-104. 被引量：1
9Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J]. Nat Med, 1996, 2(5): 561-566. 被引量：1
10Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of BCR-ABL-positive cells [J]. Blood, 1997, 90(9): 3691- 3698. 被引量：1
